Immunosuppressants, mortality, and risk of cancer

BMJ (Online)

Volumn 339, Issue 7712, 2009, Pages 59-

  Avorn, Jerry ^a   Schneeweiss, Sebastian ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROFECOXIB; ROSIGLITAZONE; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

CANCER RISK; CROHN DISEASE; EDITORIAL; EPISTEMOLOGY; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LABORATORY TEST; MORTALITY; NEOPLASM; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; NOTE; RISK FACTOR;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; RISK FACTORS;

EID: 68149099735     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b1645     Document Type: Editorial

References (10)

1. Kempen JH, Daniel E, Dunn JP, Foster CS, Gangaputra S, Hanish A, et al. Overall and cancer related mortality in patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009:338:b2480.
2. Avorn J. Powerful medicines: the benefits, risks, and costs of prescription drugs. New York: Alfred A Knopf, 2004.
3. Baciu A, Stratton K, Burke SP, eds. The future of drug safety: promoting and protecting the health of the public. Washington, DC: Institute of Medicine Press, 2006.
4. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005;58:323-337[CrossRef][Web of Science][Medline] (Pubitemid 40601980)
5. Avorn J. In defense of pharmacoepidemiology-embracing the yin and yang of drug research. N Engl J Med 2007;357:2219-2221[Free Full Text]
6. Ray WA: Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-920[Abstract/Free Full Text]
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383[CrossRef][Web of Science][Medline] (Pubitemid 17055592)
8. Elixhauser A, Steiner C, Harris R, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8e-27e.[CrossRef] (Pubitemid 128456396)
9. Schneeweiss S, Seeger J, Maclure M, Wang P, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-864 [Abstract/Free Full Text] (Pubitemid 33000813)
10. Rothman KJ. Drug-eluting versus bare-metal stents in acute myocardial infarction [letter]. N Engl J Med 2009;360:301.[Web of Science][Medline]